Jeffrey C. Goh
A5102823616- Ovarian cancer diagnosis and treatment
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Bone health and treatments
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Toxin Mechanisms and Immunotoxins
- Renal Diseases and Glomerulopathies
- Endometriosis Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Phagocytosis and Immune Regulation
- Hormonal and reproductive studies
- Reproductive Biology and Fertility
- Cervical Cancer and HPV Research
- Cancer Mechanisms and Therapy
Royal Brisbane and Women's Hospital
2014-2025
The University of Queensland
2015-2024
Queensland Health
2023
Queensland University of Technology
2023
Icon (Australia)
2022
Cancer Council Queensland
2021
Greenslopes Private Hospital
2013-2016
Gallipoli Medical Research Foundation
2016
440 Background: The phase 1/2 KEYMAKER-U03 Substudy 03B (NCT04626518) is being conducted to evaluate combination treatments for previously treated advanced ccRCC. We present results targeted therapy–containing regimens from arm B4 (pembro + belzutifan [HIF-2α inhibitor]), B5 (lenvatinib [VEGF-TKI] belzutifan), and the reference (ref) lenvatinib). Methods: Adults with histologically confirmed locally advanced/metastatic ccRCC disease progression on or after PD-(L)1 inhibitor VEGF-TKI...
552 Background: Substudy 03B of the phase 1/2 KEYMAKER-U03 trial (NCT04626518) was designed to evaluate combination treatments with pembro and investigational agents for previously treated ccRCC. We present results from arms containing only immunotherapy regimens: arm B1 (quavonlimab [qmab; anti–CTLA-4] coformulated pembro), B2 (favezelimab [fave; anti–LAG-3] B3 (pembro + MK-4830 [anti-ILT4]), reference (ref) lenvatinib). Methods: Adults histologically confirmed ccRCC disease progression on...
CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 9KD, specifically evaluating rucaparib.
Abstract Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors. Here the pan-AKT inhibitor afuresertib was given combination with paclitaxel and carboplatin (PC) patients recurrent epithelial ovarian cancer (PROC) primary platinum-refractory (PPROC). Patients Methods: Part I a 3+3 dose escalation study for cancer. received daily continuous oral at 50–150 mg/day intravenous (175 mg/m2) (AUC5) every 3 weeks six cycles followed by maintenance 125...
CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, mucin 1 targeted-dendritic cell (DC) treatment as maintenance therapy to patients with epithelial ovarian cancer (EOC).Patients (n = 56) in first (CR1) or second clinical remission (CR2) were randomized (1:1) standard care (SOC) observation CVac treatment. Ten doses administered over 56 weeks. Both groups followed for progression-free survival (PFS) overall (OS).Fifty-six...
5565 Background: The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. Prior data suggests rOCCC is a chemo-resistant disease that may respond to programmed death protein 1 (PD-1)/programmed death-ligand (PD-L1) immune checkpoint inhibition (ICI). We aimed determine the efficacy D versus PCC in pts with rOCCC. Methods: In this multicentre, open-label, randomised phase 2 trial, 9 academic centres across Singapore, South Korea and Australia, enrolled...
252 Background: Liquid biopsy assays in mCRPC are utilized for treatment eligibility of PARP inhibitors (HRR) and Pembrolizumab (MSI High). These ctDNA targeted gene panels provide translational data beyond mutations. Tumor Fraction (TF), the percentage cfDNA from tumor, is a promising prognostic efficacy biomarker pre-chemo mCRPC, potential predictive to post-chemo PSMA radioligand therapy. Methods: We analyzed run with Illumina-TSO500 CA209-7DX Ph3 trial (Nivo+chemo vs. Chemo chemo-naïve...
17 Background: Interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival (PFS) and depth PSA-response the addition [ 177 Lu]Lu-PSMA-617 (LuPSMA) to enzalutamide (enza) as first-line treatment poor-risk, metastatic, castration-resistant prostate cancer (mCRPC). Here we report effects on overall (OS) health-related quality life (HRQL) longer follow-up. Methods: We randomly assigned 162 participants (pts) enza 160 mg daily alone, or in combination...
BackgroundThe primary aim of this study was to evaluate the activity intraperitoneal bevacizumab (IP-bev) in delaying re-accumulation malignant ascites women with chemotherapy-resistant epithelial ovarian cancer (CR-EOC) who have ceased chemotherapy. Secondary outcomes were safety and quality life.MethodsWomen CR-EOC that reaccumulated within 28 days their last paracentesis (P-1) administered IP-bev 5 mg/kg following first therapeutic on (P0). Additional doses allowed at each subsequent (P1,...
A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER⁺). PARAGON is a basket trial incorporates 7 phase 2 trials investigating the activity anastrozole ER⁺ and/or progesterone (PR)-positive (PR⁺) recurrent/metastatic gynecological cancers.Postmenopausal women PR⁺ ROC, who were asymptomatic and had antigen 125 (CA125) progression after to first line...
Background The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role immune checkpoint inhibitors targeting programmed death protein 1 (PD - 1)/programmed death-ligand (PD-L1) axis in carcinoma. Primary objective To evaluate efficacy durvalumab (MEDI-4736) compared with standard chemotherapy patients Study hypothesis Patients treated will have improved progression-free survival those physician’s choice. Trial design...
To investigate whether variations in primary chemotherapy were associated with survival a nationally complete cohort of Australian women epithelial ovarian cancer (EOC).All 1192 diagnosed invasive EOC Australia 2005 identified through state-based registries. Medical record information including details treatment was obtained and data updated 2012. Those started on standard (carboplatin paclitaxel given at three-weekly intervals) after cytoreductive surgery included (n = 351) the relative...
Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must received docetaxel first, unless unsuitable for chemotherapy, despite no evidence suggesting superiority over androgen receptor signalling inhibitors (ARSIs). Our study investigated real-world treatment patterns Australian with mCRPC.The electronic CRPC Database...